Dr. Reddy's Laboratories Ltd. closed 14.68% below its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Dr. Reddy's Laboratories Ltd. closed 15.45% below its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

Brokerage firm Citi reduced its price target on Dr. Reddy's Laboratories due to mounting competitive pressures in the ...

Stay informed with the Dr Reddys Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

HYDERABAD — Dr Reddy’s Laboratories is gearing up to enter the booming global obesity drug market with a more affordable ...

Dr. Reddys Laboratories experiences a slight decrease of -0.09% in its monthly returns, despite a notable three-month return of 10.53%.

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on ...

Jio Financial Services Ltd., Tata Chemicals Ltd., Ircon International Ltd., and Dr. Reddy's Laboratories Ltd. are among the ...

Gireesh Babu, New Delhi Friday, August 8, 2025, 08:00 Hrs [IST] ...